QVITI is a Polish MedTech company developing advanced solutions for non-invasive brain stimulation and neurorehabilitation. Our flagship product, Corstim tES, is a CE-marked Class IIa medical device supporting multiple transcranial electrical stimulation modes, including tDCS, tACS and tRNS.
QVITI’s technologies are designed for professional use in neurology, neurorehabilitation, psychiatry, pain management and clinical research. We combine medical-grade hardware with evidence-based clinical applications, therapeutic protocols, professional training and direct manufacturer support.
Our development pipeline also includes an innovative VR-based home therapy solution designed to extend neurorehabilitation beyond the clinic, with immersive exercises performed by patients at home under remote professional supervision.
With QVITI technology used across more than 20 countries, we are focused on expanding our international network of clinical partners and medical device distributors and building the next generation of accessible, technology-driven neurotherapy solutions.
Business Type / 業種
Business Domain / 分野
Disease Area / 疾患領域
Modalities / モダリティ
Technologies / 技術
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術
EEN contact point selection
POLSKA AGENCJA ROZWOJU PRZEDSIEBIORCZOSCI CONTACT POINT IN WARSZAWA (POLAND) Address PANSKA 81-83 Warszawa 00834 Poland Email een@parp.gov.pl Phones +48 224327102
Product
Corstim tES - Medical-Grade Transcranial Electrical Stimulation Platform
Corstim tES is a medical-grade transcranial electrical stimulation (tES) system supporting tDCS, tACS and tRNS for clinical and research applications.
Product
VRstim - Immersive Virtual Reality Neurorehabilitation Platform
An innovative VR system for training cognitive, communication and motor skills in neurorehabilitation.
Partnership
Strategic Japan Partnership for QVITI’s Integrated Neuromodulation Platform
QVITI is seeking Japanese distribution, clinical and technology partners to introduce its patented tES/tACS platform, VR-supported neurotherapy and future therapist-supervised home-care solution in Japan.
Investment
Investment Opportunity: Scale QVITI’s Integrated Neuromodulation Platform Globally
QVITI is raising approximately €6.6M to scale its patented neuromodulation ecosystem, expand in Japan and other global markets, complete clinical and regulatory milestones, and accelerate recurring home-therapy revenue.
Project cooperation
Clinical and Research Cooperation in Neuromodulation, VR and Home Neurotherapy
QVITI seeks Japanese universities, hospitals and research institutes for joint studies, clinical pilots and technology validation using our patented tES/tACS, VR and therapist-supervised home-therapy platform.